CPAP effect on monocytes

PULMONO: Effects of CPAP treatment on monocyte subsets in patients with OSA and obesity - CPAP effect on monocytes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57612

Enrollment

Registered

2025-01-15

Start date

2026-04-03

Completion date

Unknown

Last updated

2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breath stops sleeping disorder breath stops sleeping disorder

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • >=18 years of age at presentation to the pulmonologist in the sleep clinic of ZMC, as part of the pre-treatment phase for initiation of CPAP treatment • diagnosed with obstructive sleep apnea (OSA) • BMI >= 30 kg/m2

Exclusion criteria

Exclusion criteria: <18 years of age existing anemia existing haematological malignancy Non-adherence to CPAP therapy

Design outcomes

Primary

Measure	Time frame
The main study parameter in the present study is the change in intermediate monocyte fraction (%), compared at baseline and 6 months follow-up.	—

Secondary

Measure	Time frame
In addition, differences in HbA1c (%, mmol/mol), CRP (mg/L), triglycerides (mmol/L), LDL-cholesterol (mmol/L), HDLcholesterol (mmol/L) and total cholesterol (mmol/L) will be investigated, and associated with monocyte-related parameters. Furthermore, differences in activation and differentiation markers on monocytes will be investigated and any possible confounding by any concomitant changes in medication use, dietary intake (mini-EAT), sleepiness (ESS) and physical activity (Questionnaire Physical Activity) will be monitored using short questionnaires (ESS, mini-EAT, Questionnaire Physical Activity).	—

Measure

Time frame

In addition, differences in HbA1c (%, mmol/mol), CRP (mg/L), triglycerides (mmol/L), LDL-cholesterol (mmol/L), HDLcholesterol (mmol/L) and total cholesterol (mmol/L) will be investigated, and associated with monocyte-related parameters. Furthermore, differences in activation and differentiation markers on monocytes will be investigated and any possible confounding by any concomitant changes in medication use, dietary intake (mini-EAT), sleepiness (ESS) and physical activity (Questionnaire Physical Activity) will be monitored using short questionnaires (ESS, mini-EAT, Questionnaire Physical Activity).

—

Countries

Netherlands

Contacts

Public ContactMD Kruif

Zuyderland

polilonggeneeskunde@zuyderland.nl0884597777

Outcome results